Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betibeglogene autotemcel - bluebird bio

X
Drug Profile

Betibeglogene autotemcel - bluebird bio

Alternative Names: Autologous CD34+ cells encoding βA-T87Q-globin gene therapy - bluebird bio; bb1111; BB305-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; Beta-globin-gene-therapy-bluebird-bio; beti-cel; HPV569-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; HPV569-beta-globin-gene-therapy-bluebird-bio; LentiGlobin gene therapy; LentiGlobin-HPV569; LentiGlobin™ bb1111; LentiGlobin™ BB305; Lentiviral beta AT87Q-Globin vector; lovo-cel; Lovotibeglogene autotemcel - bluebird bio; LYFGENIA; ZYNTEGLO; Zynteglo

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer bluebird bio
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Beta-thalassaemia
  • Registered Sickle cell anaemia

Most Recent Events

  • 30 Jan 2024 bluebird bio completes a phase I/II HGB-206 trial in Sickle cell anaemia in the USA (NCT02140554)
  • 11 Dec 2023 Pooled efficacy, adverse events, pharmacodynamics data from the phase I/II HGB-206 and phase III HGB-210 trial in Sickle cell anaemia released by Bluebird Bio
  • 10 Dec 2023 Efficacy and adverse events data from a phase III long-term follow up trial in Beta-thalassaemia released byBluebird Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top